These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 25727748)

  • 21. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
    García Rodríguez LA; Martín-Pérez M; Vora P; Roberts L; Balabanova Y; Brobert G; Fatoba S; Suzart-Woischnik K; Schaefer B; Ruigomez A
    BMJ Open; 2019 Sep; 9(9):e031341. PubMed ID: 31542760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
    Collings SL; Vannier-Moreau V; Johnson ME; Stynes G; Lefèvre C; Maguire A; Asmar J; Bizouard G; Duhot D; Mouquet F; Fauchier L
    Arch Cardiovasc Dis; 2018 May; 111(5):370-379. PubMed ID: 29398546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban.
    Bai Y; Shi XB; Ma CS; Lip GYH
    Am J Cardiol; 2017 Nov; 120(9):1689-1695. PubMed ID: 28844510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
    Kansal AR; Zheng Y; Pokora T; Sorensen SV
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):225-37. PubMed ID: 23953910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Economic Evaluations.
    Goudarzi Z; Ghafari Darab M; Vazin A; Hayatbakhsh A; Karimzadeh I; Jafari M; Keshavarz K; Borhani-Haghighi A
    Value Health Reg Issues; 2023 Jan; 33():99-108. PubMed ID: 36402007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation.
    Jelonek O; Gorczyca I; Bączek M; Kośmider P; Wożakowska-Kapłon B
    Kardiol Pol; 2018; 76(7):1073-1080. PubMed ID: 29441513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.
    Singh SM; Wijeysundera HC
    Curr Cardiol Rep; 2015 Aug; 17(8):61. PubMed ID: 26081245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
    Kovács T
    Orv Hetil; 2014 Oct; 155(42):1655-60. PubMed ID: 25305723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):211-9. PubMed ID: 25295718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China.
    Zhou H; Nie X; Jiang M; Dong W
    J Clin Pharm Ther; 2022 Apr; 47(4):523-530. PubMed ID: 34783090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure.
    Andreu-Cayuelas JM; Pastor-Pérez FJ; Puche CM; Mateo-Martínez A; García-Alberola A; Flores-Blanco PJ; Valdés M; Lip GY; Roldán V; Manzano-Fernández S
    Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):134-40. PubMed ID: 26607030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile.
    Barrios V; Masjuan J
    Future Cardiol; 2017 Jan; 13(1):49-64. PubMed ID: 27731650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation].
    Silva Miguel L; Ferreira J
    Rev Port Cardiol; 2016 Mar; 35(3):141-8. PubMed ID: 26928016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.